Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis

References

• Palomba S, Falbo A, Zullo F, Orio F Jr. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1–50.
   PubMed Web of Science ®Google Scholar
• Zulian E, Sartorato P, Benedini S, Baro G, Armanini D, Mantero F, Scaroni C. Spironolactone in the treatment of polycystic ovary syndrome: effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 2005;28:49–53.
   PubMed Web of Science ®Google Scholar
• De Leo V, la Marca A, Petraglia F. Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 2003;24:633–667.
   PubMed Web of Science ®Google Scholar
• Nawrocka J, Starczewski A. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Gynecol Endocrinol 2007;23:231–237.
   PubMed Web of Science ®Google Scholar
• Ganie MA, Khurana ML, Eunice M, Gupta N, Gulati M, Dwivedi SN, Ammini AC. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study. J Clin Endocrinol Metab 2004;89:2756–2762.
   PubMed Web of Science ®Google Scholar
• Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, Teo KK, Yusuf S. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003;26:290–296.
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997;18:774–800.
   PubMed Web of Science ®Google Scholar
• Polderman KH, Gooren LJ, Asscheman H, Bakker A, Heine RJ. Induction of insulin resistance by androgens and estrogens. J Clin Endocrinol Metab 1994;79:265–271.
   PubMed Web of Science ®Google Scholar
• Azziz R. How prevalent is metabolic syndrome in women with polycystic ovary syndrome? Nat Clin Pract Endocrinol Metab 2006;2:132–133.
   PubMedGoogle Scholar
• Evans DJ, Hoffmann RG, Kalkhoff RK, Kissebah AH. Relationship of androgenic activity to body fat topography, fat cell morphology, and metabolic aberrations in premenopausal women. J Clin Endocrinol Metab 1983;57:304–310.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathopshysiology, molecular aspects and clinical implications. Expert Rev Mol Med 2008;10:e3.
   PubMedGoogle Scholar
• Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metab Clin Exp 1994;43:647–654.
   PubMed Web of Science ®Google Scholar
• Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005;90:4593–4598.
   PubMed Web of Science ®Google Scholar
• Tan S, Hahn S, Benson S, Dietz T, Lahner H, Moeller LC, Schmidt M, et al. Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. Eur J Endocrinol 2007;157:669–676.
   PubMed Web of Science ®Google Scholar
• Tsilchorozidou T, Batterham RL, Conway GS. Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). Clin Endocrinol (Oxf) 2008;69:936–942.
   PubMedGoogle Scholar
• Tan BK, Heutling D, Chen J, Farhatullah S, Adya R, Keay SD, Kennedy CR, et al. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance. Diabetes 2008;57:1501–1507.
   PubMed Web of Science ®Google Scholar
• Kusaka I, Nagasaka S, Horie H, Ishibashi S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability? Diabetes Obes Metab 2008;10:1039–1046.
   PubMed Web of Science ®Google Scholar
• Corbould A. Effects of spironolactone on glucose transport and interleukin-6 secretion in adipose cells of women. Horm Metab Res 2007;39:915–918.
   PubMed Web of Science ®Google Scholar
• Corry DB, Tuck ML. The effect of aldosterone on glucose metabolism. Curr Hypertens Rep 2003;5:106–109.
   PubMed Web of Science ®Google Scholar
• Wu X, Lu K, Su Y. [Renin-angiotensin system: involvement in polycystic ovarian syndrome]. Zhonghua Fu Chan Ke Za Zhi 1997;32:428–431.
   PubMedGoogle Scholar
• Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE. A possible association between primary aldosteronism and a lower β-cell function. J Hypertens 2007;25:2125–2130.
   PubMed Web of Science ®Google Scholar
• Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, Favret G, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 2006;91:3457–3463.
   PubMed Web of Science ®Google Scholar
• Moghetti P, Tosi F, Castello R, Magnani CM, Negri C, Brun E, Furlani L, et al. The insulin resistance in women with hyperandrogenism is partially reversed by antiandrogen treatment: evidence that androgens impair insulin action in women. J Clin Endocrinol Metab 1996;81:952–960.
   PubMed Web of Science ®Google Scholar
• Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, Hayden MR, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab 2008;295:E110–E116.
   PubMed Web of Science ®Google Scholar